identifying low-burden tp53 mutations with ngs in cll
Published 1 year ago • 204 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
4:31
the impact of high and low burden tp53 mutations on risk and treatment decision in cll
-
3:13
tp53 mutations in cll: a large retrospective analysis
-
2:36
current knowledge of the tp53 mutation and its role in cll
-
1:07
testing for ighv and tp53 mutations to guide treatment decisions in cll
-
2:02
the prognostic impact of tp53 and ighv status in the era of targeted therapies in cll
-
30:20
hls pathology - lymphoid neoplasms ( all - cll )
-
6:21
p53 in cell cycle regulation | p53 and cancer | p53 tumor suppressor.
-
3:23
molecular profiling
-
1:08
cll genomics: p53 mutations and deletions
-
2:23
significance of eric study in identifying p53 mutants in cll
-
2:27
the importance of tp53 & ighv testing before treatment initiation in cll
-
3:08
recent updates on tp53 mutation in cll
-
2:14
the importance of tp53 testing in cll
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
1:26
the role of tp53 in cll
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
0:54
re-testing in cll: fish analysis and tp53 screening
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
2:08
identifying tp53 disruptions: a diagnostic measure in cll
-
2:12
the impact of genetic abnormalities on treatment decisions in cll
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
2:33
identifying novel biomarkers and advancing the classification system in cll